Lung cancer
Conditions
Interventions
case group:First generation of EGFR-TKI
Health people goup:Nil
Sponsors
The First Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Patients are older than 18 years with lung adenocarcinoma, confirmed by histopathology and immunohistochemistry and positive for common mutations in EGFR detected by histological section; (2) Patients willing to choose the first generation of EGFR-TKI as the first-line treatment drugs; The healthy control group was selected as follows: Healthy people aged 40-60 years old who without infectious diseases in recent three months.
Exclusion criteria
Exclusion criteria: Patients with primary resistance to EGFR-TKI were excluded ,who has rare gene mutation such as L858R point mutation, exon 20 mutation and primary mutation T790M. Combination of angiogenesis inhibitors directly targeting VEGF and angiogenesis inhibitors (sorafenib) targeting other signaling molecules in the VEGF pathway. Complicated with myocardial infarction, diabetes and other serious vascular disease patients, long-term smoking patients, cardiovascular, rheumatic, infection, pregnancy patients. Combined with other systems of primary malignancies. Researchers believe there are other important diseases that are not suitable for participants in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of endothelial progenitor cells;function of endothelial progenitor cells; | — |
Countries
China
Contacts
Public ContactDu Hongchun
The First Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed